Eckert & Ziegler stock (DE0005659700): Nuclear medicine specialist with rising market cap

Eckert & Ziegler SE, a German nuclear medicine and isotope technology group, has seen its market capitalization grow to around €984 million in early May 2026, reflecting continued investor interest in radiopharmaceuticals and nuclear diagnostics.

Eckert & Ziegler SE, a German specialist in nuclear medicine and isotope technology, has seen its market capitalization rise to about €984 million as of early May 2026, according to market?data provider TipRanks, which tracks the company’s equity value in real time.TipRanks as of May 07, 2026

Over the past year the market cap has increased by roughly 21.5 percent, underscoring sustained demand for companies exposed to radiopharmaceuticals, nuclear diagnostics and related medical?technology infrastructure.TipRanks as of May 07, 2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eckert & Ziegler SE
• Sector/industry: Healthcare / nuclear medicine and isotope technology
• Headquarters/country: Germany
• Core markets: Europe, North America, Asia Pacific
• Key revenue drivers: Radiopharmaceuticals, isotope?based diagnostics and therapy, nuclear?medicine infrastructure
• Home exchange/listing venue: Frankfurt Stock Exchange (ticker: EZAG)
• Trading currency: Euro

Eckert & Ziegler: core business model

Eckert & Ziegler SE operates as a vertically integrated provider of products and services for nuclear medicine, radiation therapy and related industrial applications, with a focus on radioisotopes and radiopharmaceuticals.Eckert & Ziegler corporate website

The group manufactures and distributes radioactive sources, radiopharmaceuticals and specialized equipment used in diagnostic imaging and targeted cancer therapies, serving hospitals, research institutions and industrial customers worldwide.Eckert & Ziegler corporate website

Through subsidiaries such as Eckert & Ziegler Analytics, Inc. in the United States, the company supplies isotope technology for medical, industrial and research applications, giving it a direct footprint in the North American healthcare market.Monster Jobs listing as of 2025

Main revenue and product drivers for Eckert & Ziegler

Key revenue streams for Eckert & Ziegler include the sale of radiopharmaceuticals for diagnostic imaging (such as PET and SPECT tracers) and therapeutic agents used in targeted radionuclide therapy, which are increasingly deployed in oncology and cardiology.Eckert & Ziegler corporate website

The company also earns from contract manufacturing and logistics services for radioactive materials, as well as from the design and supply of radiation?source systems for industrial and medical?device applications.Eckert & Ziegler corporate website

Recent industry reports on the Asia Pacific nuclear?medicine market highlight strong growth in demand for radiopharmaceuticals, with the regional market projected to expand at a compound annual growth rate of about 17 percent through 2030, a trend that benefits Eckert & Ziegler’s licensing and distribution activities in that region.MarketsandMarkets as of January 2025

Why Eckert & Ziegler matters for US investors

For US investors, Eckert & Ziegler offers indirect exposure to the global nuclear?medicine and radiopharmaceutical sector through a listed European company with operations in North America.Eckert & Ziegler corporate website

The company’s US subsidiary Eckert & Ziegler Analytics, Inc. supplies isotope technology to medical and industrial customers, linking its performance to healthcare spending and regulatory developments in the United States.Monster Jobs listing as of 2025

As the US market continues to adopt advanced nuclear?imaging techniques and targeted radionuclide therapies, demand for Eckert & Ziegler’s products and services may grow, although investors should also monitor regulatory, reimbursement and supply?chain risks.MarketsandMarkets as of January 2025

Conclusion

Eckert & Ziegler SE is a German?listed specialist in nuclear medicine and isotope technology whose market capitalization has grown to around €984 million in early May 2026, reflecting investor interest in radiopharmaceuticals and nuclear?medicine infrastructure.TipRanks as of May 07, 2026

The company generates revenue from radiopharmaceuticals, diagnostic and therapeutic isotopes, and related services, with operations in Europe, North America and Asia Pacific, including a US subsidiary that supplies isotope technology to medical and industrial customers.Eckert & Ziegler corporate website

For US investors, Eckert & Ziegler offers exposure to a niche but growing segment of healthcare technology, though the stock’s performance will depend on regulatory developments, reimbursement policies, supply?chain stability and broader trends in nuclear medicine and oncology.MarketsandMarkets as of January 2025

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.